腾讯网25 天
聚焦 EGFR 突变 III 期不可切除 NSCLC，解读靶向巩固治疗新进展
2024 年，非小细胞肺癌（NSCLC）治疗领域迎来了累累硕果。尤其是针对 EGFR 突变 III 期不可切除 NSCLC 的靶向巩固治疗研究，取得了令人振奋的突破性 ...
The EMBO Journal10 天
Ephrin A1 functions as a ligand of EGFR to promote EMT and metastasis in gastric cancer
Epidermal growth factor receptor (EGFR) is a major driver of cancer dissemination and target for anti-cancer therapies but ...